Natural Product (NP) Details
| General Information of the NP (ID: NP1886) | |||||
|---|---|---|---|---|---|
| Name |
Scutellarin
|
||||
| Synonyms |
Breviscapin; Scutellarein-7-glucuronide; Breviscapine; Scutellarein-7beta-D-glucuronide; Scutellarein-7beta-D-glucuronoside; Scutellarein-7-O-beta-D-glucuronide; UNII-16IGP0ML9A; SCUTELLAREIN 7-O-GLUCURONIDE; Scutellarein 7-O-beta-D-glucuronide; 16IGP0ML9A; CHEMBL487805; (2S,3S,4S,5R,6S)-6-((5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; CHEBI:61278; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl; 116122-36-2; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranosiduronic acid; dengzhanhua; Scutellarine; new-breviscapine; Scutellarin,(S); (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yloxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; MEGxp0_000554; SCHEMBL4211849; Scutellarin, analytical standard; DTXSID60921924; BCP11536; Flavone, 4',5,6,7-tetrahydroxy-, 7-beta-D-glucopyranuronoside; HY-N0751; BDBM50242284; MFCD01861503; s3810; ZINC21992916; AKOS016009652; AC-6073; CCG-269364; CCG-269365; CS-4273; BS-16838; O359; AB0016413; N1753; A12117; W-2538; 740S018; Q410712; Breviscapin;Scutellarein-7-glucuronide;Scutellarin B; Q-100351; 5,6-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl hexopyranosiduronic acid; 7-(beta-d-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7- yl]oxy-3,4,5-trihydroxy-oxane-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; 4H-1-Benzopyran-4-one, 7-(.beta.-D-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-; Glucopyranosiduronic acid, 5,6-dihydroxy-2-(p-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl, beta-D-
Click to Show/Hide
|
||||
| Species Origin | Scutellaria indica ... | Click to Show/Hide | |||
| Scutellaria indica | |||||
| Disease | Renal cell carcinoma [ICD-11: 2C90] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-6.65
MDCK Permeability
-5.038
PAMPA
+++
HIA
- - -
Distribution
VDss
0.016
PPB
82.8%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
++
HLM Stability
- - -
Excretion
CLplasma
1.908
T1/2
3.717
Toxicity
DILI
+++
Rat Oral Acute Toxicity
- - -
FDAMDD
- -
Respiratory
- - -
Human Hepatotoxicity
-
Ototoxicity
+
Drug-induced Nephrotoxicity
-
Drug-induced Neurotoxicity
- - -
Hematotoxicity
- - -
Genotoxicity
++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C21H18O12
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O
|
||||
| InChI |
1S/C21H18O12/c22-8-3-1-7(2-4-8)10-5-9(23)13-11(31-10)6-12(14(24)15(13)25)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-22,24-28H,(H,29,30)/t16-,17-,18+,19-,21+/m0/s1
|
||||
| InChIKey |
DJSISFGPUUYILV-ZFORQUDYSA-N
|
||||
| CAS Number |
CAS 27740-01-8
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Activity | PKM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | ||
| HT29 | CVCL_A8EZ | Colorectal adenocarcinoma | Mus musculus | |||
| In-vivo Model | For a xenograft model, 5 * 106 OR-SW480 cells were subcutaneously injected into the right armpit of 4-week-old female immunodeficient nude BALB/c mice. | |||||
| Experimental
Result(s) |
Scutellarin resensitizes oxaliplatin-resistant CRC cells to oxaliplatin treatment through inhibition of PKM2. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP6 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Scutellarin sensitizes 5FU-evoked colon cancer cell apoptosis through enhanced caspase-6 activation. | |||||
| β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MET | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| In-vivo Model | A549/DDP-Luc cells (4*106) were subcutaneously injected into the right flank of 4-to-6 week-old female BALB/c nude mice. | |||||
| Experimental
Result(s) |
Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Extracellular signal-regulated kinase 1 (ERK1) | Molecule Info | [5] | |
| Extracellular signal-regulated kinase 2 (ERK2) | Molecule Info | [5] | ||
| Transforming growth factor beta 1 (TGFB1) | Molecule Info | [5] | ||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | ErbB signaling pathway | |||
| 3 | Ras signaling pathway | |||
| 4 | Rap1 signaling pathway | |||
| 5 | cGMP-PKG signaling pathway | |||
| 6 | cAMP signaling pathway | |||
| 7 | Chemokine signaling pathway | |||
| 8 | HIF-1 signaling pathway | |||
| 9 | FoxO signaling pathway | |||
| 10 | Sphingolipid signaling pathway | |||
| 11 | Oocyte meiosis | |||
| 12 | mTOR signaling pathway | |||
| 13 | PI3K-Akt signaling pathway | |||
| 14 | Adrenergic signaling in cardiomyocytes | |||
| 15 | Vascular smooth muscle contraction | |||
| 16 | Dorso-ventral axis formation | |||
| 17 | TGF-beta signaling pathway | |||
| 18 | Axon guidance | |||
| 19 | VEGF signaling pathway | |||
| 20 | Osteoclast differentiation | |||
| 21 | Focal adhesion | |||
| 22 | Adherens junction | |||
| 23 | Gap junction | |||
| 24 | Signaling pathways regulating pluripotency of stem cells | |||
| 25 | Platelet activation | |||
| 26 | Toll-like receptor signaling pathway | |||
| 27 | NOD-like receptor signaling pathway | |||
| 28 | Natural killer cell mediated cytotoxicity | |||
| 29 | T cell receptor signaling pathway | |||
| 30 | B cell receptor signaling pathway | |||
| 31 | Fc epsilon RI signaling pathway | |||
| 32 | Fc gamma R-mediated phagocytosis | |||
| 33 | TNF signaling pathway | |||
| 34 | Circadian entrainment | |||
| 35 | Long-term potentiation | |||
| 36 | Neurotrophin signaling pathway | |||
| 37 | Retrograde endocannabinoid signaling | |||
| 38 | Glutamatergic synapse | |||
| 39 | Cholinergic synapse | |||
| 40 | Serotonergic synapse | |||
| 41 | Long-term depression | |||
| 42 | Regulation of actin cytoskeleton | |||
| 43 | Insulin signaling pathway | |||
| 44 | GnRH signaling pathway | |||
| 45 | Progesterone-mediated oocyte maturation | |||
| 46 | Estrogen signaling pathway | |||
| 47 | Melanogenesis | |||
| 48 | Prolactin signaling pathway | |||
| 49 | Thyroid hormone signaling pathway | |||
| 50 | Oxytocin signaling pathway | |||
| 51 | Type II diabetes mellitus | |||
| 52 | Aldosterone-regulated sodium reabsorption | |||
| 53 | Alzheimer's disease | |||
| 54 | Prion diseases | |||
| 55 | Alcoholism | |||
| 56 | Shigellosis | |||
| 57 | Salmonella infection | |||
| 58 | Pertussis | |||
| 59 | Leishmaniasis | |||
| 60 | Chagas disease (American trypanosomiasis) | |||
| 61 | Toxoplasmosis | |||
| 62 | Tuberculosis | |||
| 63 | Hepatitis C | |||
| 64 | Hepatitis B | |||
| 65 | Influenza A | |||
| 66 | Pathways in cancer | |||
| 67 | Viral carcinogenesis | |||
| 68 | Proteoglycans in cancer | |||
| 69 | Colorectal cancer | |||
| 70 | Renal cell carcinoma | |||
| 71 | Pancreatic cancer | |||
| 72 | Endometrial cancer | |||
| 73 | Glioma | |||
| 74 | Prostate cancer | |||
| 75 | Thyroid cancer | |||
| 76 | Melanoma | |||
| 77 | Bladder cancer | |||
| 78 | Chronic myeloid leukemia | |||
| 79 | Acute myeloid leukemia | |||
| 80 | Non-small cell lung cancer | |||
| 81 | Central carbon metabolism in cancer | |||
| 82 | Choline metabolism in cancer | |||
| 83 | Cytokine-cytokine receptor interaction | |||
| 84 | Cell cycle | |||
| 85 | Endocytosis | |||
| 86 | Hippo signaling pathway | |||
| 87 | Intestinal immune network for IgA production | |||
| 88 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 89 | Malaria | |||
| 90 | Amoebiasis | |||
| 91 | HTLV-I infection | |||
| 92 | Inflammatory bowel disease (IBD) | |||
| 93 | Rheumatoid arthritis | |||
| 94 | Hypertrophic cardiomyopathy (HCM) | |||
| 95 | Dilated cardiomyopathy | |||
| 96 | MicroRNAs in cancer | |||
| NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
| 2 | TCR Signaling Pathway | |||
| 3 | IL3 Signaling Pathway | |||
| 4 | TGF_beta_Receptor Signaling Pathway | |||
| 5 | IL2 Signaling Pathway | |||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | Click to Show/Hide | ||
| 2 | Angiogenesis | |||
| 3 | Apoptosis signaling pathway | |||
| 4 | B cell activation | |||
| 5 | EGF receptor signaling pathway | |||
| 6 | Endothelin signaling pathway | |||
| 7 | FGF signaling pathway | |||
| 8 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 9 | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | |||
| 10 | Integrin signalling pathway | |||
| 11 | Interferon-gamma signaling pathway | |||
| 12 | Interleukin signaling pathway | |||
| 13 | PDGF signaling pathway | |||
| 14 | Parkinson disease | |||
| 15 | TGF-beta signaling pathway | |||
| 16 | T cell activation | |||
| 17 | Toll receptor signaling pathway | |||
| 18 | VEGF signaling pathway | |||
| 19 | Ras Pathway | |||
| 20 | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
| 21 | CCKR signaling map ST | |||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| 3 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| 4 | Insulin Signalling | |||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
| 2 | Endothelins | |||
| 3 | BCR signaling pathway | |||
| 4 | Signaling events mediated by PRL | |||
| 5 | ErbB4 signaling events | |||
| 6 | GMCSF-mediated signaling events | |||
| 7 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 8 | S1P3 pathway | |||
| 9 | EPHB forward signaling | |||
| 10 | Osteopontin-mediated events | |||
| 11 | S1P4 pathway | |||
| 12 | Presenilin action in Notch and Wnt signaling | |||
| 13 | TRAIL signaling pathway | |||
| 14 | CDC42 signaling events | |||
| 15 | Signaling events regulated by Ret tyrosine kinase | |||
| 16 | Angiopoietin receptor Tie2-mediated signaling | |||
| 17 | S1P1 pathway | |||
| 18 | Regulation of Telomerase | |||
| 19 | Netrin-mediated signaling events | |||
| 20 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
| 21 | Glucocorticoid receptor regulatory network | |||
| 22 | Arf6 downstream pathway | |||
| 23 | mTOR signaling pathway | |||
| 24 | IL2-mediated signaling events | |||
| 25 | EGF receptor (ErbB1) signaling pathway | |||
| 26 | Ras signaling in the CD4+ TCR pathway | |||
| 27 | Ceramide signaling pathway | |||
| 28 | Integrins in angiogenesis | |||
| 29 | IFN-gamma pathway | |||
| 30 | ErbB1 downstream signaling | |||
| 31 | ATF-2 transcription factor network | |||
| 32 | ErbB2/ErbB3 signaling events | |||
| 33 | ALK1 signaling events | |||
| 34 | PDGFR-beta signaling pathway | |||
| 35 | Neurotrophic factor-mediated Trk receptor signaling | |||
| 36 | Syndecan-1-mediated signaling events | |||
| 37 | Retinoic acid receptors-mediated signaling | |||
| 38 | Nongenotropic Androgen signaling | |||
| 39 | CXCR3-mediated signaling events | |||
| 40 | VEGFR1 specific signals | |||
| 41 | Regulation of cytoplasmic and nuclear SMAD2/3 signaling | |||
| 42 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 43 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 44 | Syndecan-2-mediated signaling events | |||
| 45 | Cellular roles of Anthrax toxin | |||
| 46 | S1P2 pathway | |||
| 47 | Trk receptor signaling mediated by the MAPK pathway | |||
| 48 | Downstream signaling in naï | |||
| 49 | ||||
| 50 | VEGFR3 signaling in lymphatic endothelium | |||
| 51 | Alpha-synuclein signaling | |||
| 52 | FGF signaling pathway | |||
| 53 | Glypican 1 network | |||
| 54 | IL27-mediated signaling events | |||
| 55 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 56 | AP-1 transcription factor network | |||
| 57 | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| 58 | TGF-beta receptor signaling | |||
| 59 | IL12 signaling mediated by STAT4 | |||
| 60 | Class IB PI3K non-lipid kinase events | |||
| 61 | BMP receptor signaling | |||
| 62 | Signaling events mediated by focal adhesion kinase | |||
| Reactome | MAPK3 (ERK1) activation | Click to Show/Hide | ||
| 2 | RAF-independent MAPK1/3 activation | |||
| 3 | ISG15 antiviral mechanism | |||
| 4 | ERK/MAPK targets | |||
| 5 | Regulation of actin dynamics for phagocytic cup formation | |||
| 6 | Oxidative Stress Induced Senescence | |||
| 7 | Senescence-Associated Secretory Phenotype (SASP) | |||
| 8 | Oncogene Induced Senescence | |||
| 9 | FCERI mediated MAPK activation | |||
| 10 | Regulation of HSF1-mediated heat shock response | |||
| 11 | NCAM signaling for neurite out-growth | |||
| 12 | Activation of the AP-1 family of transcription factors | |||
| 13 | Thrombin signalling through proteinase activated receptors (PARs) | |||
| 14 | Negative regulation of FGFR1 signaling | |||
| 15 | Negative regulation of FGFR2 signaling | |||
| 16 | Negative regulation of FGFR3 signaling | |||
| 17 | Negative regulation of FGFR4 signaling | |||
| 18 | RHO GTPases Activate WASPs and WAVEs | |||
| 19 | RAF/MAP kinase cascade | |||
| 20 | MAP2K and MAPK activation | |||
| 21 | Negative feedback regulation of MAPK pathway | |||
| 22 | Negative regulation of MAPK pathway | |||
| 23 | Signal attenuation | |||
| 24 | Advanced glycosylation endproduct receptor signaling | |||
| 25 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| 26 | Growth hormone receptor signaling | |||
| 27 | Platelet degranulation | |||
| 28 | Molecules associated with elastic fibres | |||
| 29 | TGF-beta receptor signaling activates SMADs | |||
| 30 | TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | |||
| 31 | Syndecan interactions | |||
| 32 | ECM proteoglycans | |||
| 33 | SMAD2/3 Phosphorylation Motif Mutants in Cancer | |||
| 34 | SMAD2/3 MH2 Domain Mutants in Cancer | |||
| 35 | TGFBR2 Kinase Domain Mutants in Cancer | |||
| 36 | TGFBR1 KD Mutants in Cancer | |||
| 37 | TGFBR1 LBD Mutants in Cancer | |||
| 38 | Transcriptional regulation of white adipocyte differentiation | |||
| 39 | MAPK1 (ERK2) activation | |||
| 40 | Golgi Cisternae Pericentriolar Stack Reorganization | |||
| 41 | Recycling pathway of L1 | |||
| 42 | CREB phosphorylation through the activation of Ras | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| 3 | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| 4 | Serotonin HTR1 Group and FOS Pathway | |||
| 5 | TCR Signaling Pathway | |||
| 6 | Hypothetical Network for Drug Addiction | |||
| 7 | EPO Receptor Signaling | |||
| 8 | TGF Beta Signaling Pathway | |||
| 9 | Regulation of Actin Cytoskeleton | |||
| 10 | IL-2 Signaling Pathway | |||
| 11 | Insulin Signaling | |||
| 12 | MAPK Cascade | |||
| 13 | IL-4 Signaling Pathway | |||
| 14 | MAPK Signaling Pathway | |||
| 15 | IL-6 signaling pathway | |||
| 16 | Signaling of Hepatocyte Growth Factor Receptor | |||
| 17 | Kit receptor signaling pathway | |||
| 18 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
| 19 | IL-3 Signaling Pathway | |||
| 20 | Cardiac Hypertrophic Response | |||
| 21 | MAP kinase activation in TLR cascade | |||
| 22 | Fc epsilon receptor (FCERI) signaling | |||
| 23 | RAF/MAP kinase cascade | |||
| 24 | Structural Pathway of Interleukin 1 (IL-1) | |||
| 25 | Genes and (Common) Pathways Underlying Drug Addiction | |||
| 26 | Signal Transduction of S1P Receptor | |||
| 27 | PDGF Pathway | |||
| 28 | Alpha 6 Beta 4 signaling pathway | |||
| 29 | Spinal Cord Injury | |||
| 30 | BDNF signaling pathway | |||
| 31 | Integrated Pancreatic Cancer Pathway | |||
| 32 | Oncostatin M Signaling Pathway | |||
| 33 | Corticotropin-releasing hormone | |||
| 34 | Interleukin-11 Signaling Pathway | |||
| 35 | AGE/RAGE pathway | |||
| 36 | TNF alpha Signaling Pathway | |||
| 37 | Prostate Cancer | |||
| 38 | Signaling Pathways in Glioblastoma | |||
| 39 | TSLP Signaling Pathway | |||
| 40 | IL-9 Signaling Pathway | |||
| 41 | IL17 signaling pathway | |||
| 42 | Alzheimers Disease | |||
| 43 | IL-7 Signaling Pathway | |||
| 44 | TWEAK Signaling Pathway | |||
| 45 | FSH signaling pathway | |||
| 46 | Leptin signaling pathway | |||
| 47 | RANKL/RANK Signaling Pathway | |||
| 48 | IL-1 signaling pathway | |||
| 49 | Thrombin signalling through proteinase activated receptors (PARs) | |||
| 50 | Signaling by Insulin receptor | |||
| 51 | Signaling by FGFR | |||
| 52 | RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | |||
| 53 | L1CAM interactions | |||
| 54 | Advanced glycosylation endproduct receptor signaling | |||
| 55 | Apoptosis Modulation and Signaling | |||
| 56 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 57 | Regulation of toll-like receptor signaling pathway | |||
| 58 | Osteopontin Signaling | |||
| 59 | IL-5 Signaling Pathway | |||
| 60 | DNA Damage Response (only ATM dependent) | |||
| 61 | Senescence and Autophagy in Cancer | |||
| 62 | ACE Inhibitor Pathway | |||
| 63 | Cytokines and Inflammatory Response | |||
| 64 | Endochondral Ossification | |||
| 65 | TGF beta Signaling Pathway | |||
| 66 | NRF2 pathway | |||
| 67 | Nuclear Receptors Meta-Pathway | |||
| 68 | Vitamin D Receptor Pathway | |||
| 69 | Aryl Hydrocarbon Receptor Pathway | |||
| 70 | Extracellular vesicle-mediated signaling in recipient cells | |||
| 71 | Dopaminergic Neurogenesis | |||
| 72 | Endoderm Differentiation | |||
| 73 | Hematopoietic Stem Cell Differentiation | |||
| 74 | Differentiation Pathway | |||
| 75 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| 76 | Syndecan interactions | |||
| 77 | Host Interactions with Influenza Factors | |||
| 78 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 79 | Signaling by TGF-beta Receptor Complex | |||
| 80 | Extracellular matrix organization | |||
| 81 | Elastic fibre formation | |||
| 82 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| 83 | Cardiac Progenitor Differentiation | |||
| 84 | Adipogenesis | |||
| 85 | Allograft Rejection | |||
| 86 | Cell Cycle | |||
| 87 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
| 88 | Vitamin A and Carotenoid Metabolism | |||
| 89 | ErbB Signaling Pathway | |||
| 90 | EGF/EGFR Signaling Pathway | |||
| 91 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 92 | Bladder Cancer | |||
| 93 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| 94 | Nanoparticle-mediated activation of receptor signaling | |||
| 95 | EBV LMP1 signaling | |||
| 96 | Nifedipine Activity | |||
| 97 | Aryl Hydrocarbon Receptor | |||
| 98 | B Cell Receptor Signaling Pathway | |||
| 99 | Endothelin Pathways | |||
| 100 | Integrated Breast Cancer Pathway | |||
| 101 | Opioid Signalling | |||
| 102 | Integrin-mediated Cell Adhesion | |||
| 103 | Heart Development | |||
| 104 | Type II diabetes mellitus | |||
| 105 | Angiogenesis | |||
| 106 | Physiological and Pathological Hypertrophy of the Heart | |||